News
Newsroom
Keep up to date with our latest news and findings;
- Dec 2021: Betagenon co-founder publishes new data showing reversal of gene expression, chromatin changes and expression of stressmarkers in beta cells in diet-induced obese mice by the pan-Activator O304; Pan‑AMPK activator O304
prevents gene expression changes and remobilisation of histone marks in islets of diet‑induced obese mice (PDF) - Nov 2021: Betagenon co-founder publishes study demonstrating that pan-AMPK activator O304 acts as an exercise mimetic in aged mice; AMPK activator O304 improves metabolic and cardiac function, and exercise capacity in aged mice (PDF)
- June 2021: Betagenon AB announces investment and collaboration with Hong Kong-based MCG Technology Group Ltd
- May 2021: Betagenon AB announces new CEO and new Chairman of the Board
- August 2020: Start of Bridging PK clinical trial of O304
- January 2020: China-Based Ivy Capital Invests in Betagenon’s Clinical Stage AMPK Activator Program
- January 2019: Jan M Lundberg joins Betagenon´s Board of Directors
- June 2018: New Published data on Betagenon´s leading drug O304 in JCI insight and on europehealth.eu
- May 2018: AMPK activator O304 – A novel potential treatment for diabetic kidney disease
- November 2017: Betagenon/Baltic Bio announces positive results from the Phase IIa trial
- November 2016: Betagenon Awarded Competitive EU-grant
- August 2016: Start of Phase IIa clinical trial of AMPK activator O304
- April 2016: Successful completion of Phase I clinical trial of AMPK activator O304
- Feb 2015: O304 act as an oral PCSK9 inhibitor
- Feb 2015: Succesful completion of Phase 1a clinical trial with AMPK activator O304
- Mars 2014: First time in man-AMPK activator O304